Summary
Biogen Idec Inc. (BIIB) filed an 8-K on October 28, 2011, primarily to announce its financial results for the third quarter ended September 30, 2011. The filing incorporates by reference a press release that details the company's operational and financial performance for the period. Investors should note that this information is being furnished and not formally "filed" under certain sections of the Exchange Act, meaning it is not subject to the same liability provisions. While the 8-K itself is procedural, the attached press release (Exhibit 99) is the substantive content for investors. It provides the key financial figures and operational highlights for the quarter. Investors seeking detailed performance metrics, revenue figures, earnings per share, and any forward-looking statements or significant business updates would need to refer to the press release itself.
Key Highlights
- 1Biogen Idec announced its third-quarter 2011 financial results and operational performance.
- 2The results were detailed in a press release furnished as Exhibit 99 to the 8-K filing.
- 3The filing serves to officially announce the release of these quarterly results to the market.
- 4Information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- 5The report includes standard closing signatures and an exhibit index.
- 6Exhibit 99 contains the press release with the actual financial and operational data.